TickerKhojComparison · NSE · data 2026-11-02
Eris Lifesciences Ltd vs NATCO Pharma Limited
In plain words
Size: Eris Lifesciences Ltd is about 1 times the market value of NATCO Pharma Limited.
Valuation (P/E): Eris Lifesciences Ltd 23.1 vs NATCO Pharma Limited 12.4.
Profit growth over 3 years: NATCO Pharma Limited 25.6% a year vs Eris Lifesciences Ltd 17.5% a year.
Debt to equity: Eris Lifesciences Ltd 0.6 vs NATCO Pharma Limited 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ERIS | NATCOPHARM | |
|---|---|---|
| Price | ₹1,184.4 | ₹784.7 |
| Market cap | ₹16,088 cr | ₹15,350 cr |
| P/E | 23.1 | 12.4 |
| P/B | 4 | — |
| ROE | 18.3% | 16.9% |
| ROCE | 15.6% | 15.6% |
| Debt / equity | 0.6 | 0.08 |
| Operating margin | 26.3% | 24.6% |
| Dividend yield | 0.62% | 0.57% |
| Sales growth, 3 years (yearly) | 22.9% | 14.5% |
| Profit growth, 3 years (yearly) | 17.5% | 25.6% |
| 1-year return | -27.2% | -5.1% |
| Revenue, last 12 months | ₹3,330 cr | ₹3,485 cr |
| Net profit, last 12 months | ₹708 cr | ₹1,144 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹184 cr | ₹207 cr |
| Quarter profit vs a year earlier | +52.9% | -57.0% |
| Promoter holding | 54.74% | 49.39% |
| Health check | Strong (7/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Eris Lifesciences Ltd or NATCO Pharma Limited?
Eris Lifesciences Ltd trades at the higher P/E (23.1 against 12.4). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Eris Lifesciences Ltd (18.3% against 16.9%).
Which carries more debt?
Eris Lifesciences Ltd has the higher debt-to-equity ratio (0.6 against 0.08).